Method for producing purified influenza virus antigen
The present invention aims to provide a method which enables efficient removal of impurities such as the host proteins from an influenza virus culture liquid by a simple operation, allowing separation and purification of an influenza virus antigen. The method of the present invention for producing a purified influenza virus antigen comprises the step of treating a sample containing an influenza virus with a surfactant, the step of bringing the sample after the treatment into contact with hydroxyapatite in the presence of the surfactant, and the step of recovering a hydroxyapatite-non-adsorbed fraction.
1. A method for producing a purified influenza virus hemagglutinin (HA) antigen, said method comprising the steps of:
treating a sample containing the influenza virus HA antigen with a surfactant;
bringing said sample after the treatment into contact with hydroxyapatite in the presence of said surfactant under conditions where most of the HA antigen is not adsorbed by hydroxyapatite; and
recovering a fraction not adsorbed by the hydroxyapatite,
wherein said surfactant comprises at least one of an amphoteric surfactant 3-(3-cholamidepropyl)dimethylammonio-1-propanesulphonate, an nonionic surfactant polyoxyethyeneglycol p-t-octylphenyl ether and an anioni surfactant deoxycholic acid or a salt thereof.
2. The production method according to claim 1 , wherein said sample containing an influenza virus antigen is an influenza virus grown by animal cell culture or chicken egg culture.
3. The production method according to claim 1 , wherein said sample containing an influenza virus antigen is culture liquid of a recombinant cell produced by incorporating a gene for producing an influenza virus antigen to an animal cell or insect cell.
4. The production method according to any one of claims 1 to 3 , wherein said surfactant treatment is carried out with a surfactant at a concentration of 0.05% to 20%.
5. The production method according to claim 1 , wherein said surfactant comprises the amphoteric surfactant 3-(3-cholamidepropyl)dimethylammonio-1-propanesulphonate (CHAPS).
6. The production method according to claim 1 , wherein said surfactant comprises the nonionic surfactant polyoxyethyleneglycol p-t-octylphenyl ether.
7. The production method according to claim 1 , wherein said surfactant comprises the anionic surfactant deoxycholic acid or a salt thereof.
8. The production method according to claim 5 , wherein said amphoteric surfactant is CHAPS and said surfactant treatment is carried out with a surfactant at a concentration of 0.5% to 20%.
9. The production method according to claim 6 , wherein said nonionic surfactant is polyoxyethyleneglycol p-t-octylphenyl ether and said surfactant treatment is carried out with the surfactant at a concentration of 00.5% to 3%.
10. The production method according to claim 7 , wherein said anionic surfactant is deoxycholic acid or a salt thereof and said surfactant treatment is carried out with the surfactant at a concentration of 1% to 20%.
11. The production method according to claim 1 , wherein insoluble matter is removed from the sample after the surfactant treatment before the sample is brought into contact with hydroxyapatite.
12. The production method according to claim 1 , wherein the sample after the surfactant treatment is brought into contact with hydroxyapatite under the condition of pH 6 to 10.
13. The production method according to claim 1 , wherein, in said step of bringing the sample into contact with said surfactant and hydroxyapatite, hydroxyapatite is added to said treated sample in a batch-wise manner and the supernatant is then recovered as the fraction not adsorbed by hydroxyapatite.
14. The production method according to claim 1 , wherein, in said step of bringing the sample into contact with hydroxyapatite, said treated sample is applied to a column filled with hydroxyapatite and the pass-through fraction from the column is recovered.
15. The production method according to claim 1 , further comprising:
adding an adjuvant and/or antiseptic to the recovered fraction not adsorbed by the hydroxyapatite to produce an influenza vaccine.
16. The production method according to claim 6 , wherein said nonionic surfactant is polyoxyethyleneglycol p-t-octylphenyl ether polyoxyethyleneglycol (Triton X-100).
17. The production method according to claim 7 , wherein said anionic surfactant is sodium deoxycholate (DOC).